Franciscan Health signed a three-year, sole-source agreement with Carestream Health for room-based and portable digital radiography systems that includes Carestream’s DRX-Evolution Plus and DRX-Ascend room-based systems as well as its DRX-Revolution Mobile X-ray system. The group also can purchase Carestream’s DRX-Excel Plus radiography/fluoroscopy system and DRX detectors as part of a dual-source agreement.

Carolina Breast Imaging Specialists of Greenville, North Carolina today announced it is the first U.S. site to begin using iCAD’s advanced artificial intelligence technology, PowerLook Tomo Detection, in conjunction with GE Healthcare’s tomosynthesis platform.

Up to 45 percent of all cancer patients develop brain metastases, tumors that spread to the brain from cancers located elsewhere in the body. As the number of patients affected by metastatic brain tumors grows, targeted treatment options, like the Gamma Knife radiosurgery, may offer better tumor control and symptom management.

West Hertfordshire Hospitals NHS Trust (West Herts) located in the South East of the UK and Carestream have signed and ...

Siemens Healthineers and the Fraunhofer Institute for Medical Image Computing MEVIS announced the formation of a new research alliance to develop decision support systems for physicians based on deep machine learning. The partners will discuss their joint efforts at the German Radiology Congress, May 24-27 in Leipzig, Germany.

Scientists from the Netherlands and Russia designed and tested a new metasurface-based technology for enhancing the local sensitivity of magnetic resonance imaging (MRI) scanners on humans for the first time. The metasurface consists of thin resonant strips arranged periodically. Placed under a patient's head, it provided much higher signals from the local brain region.

The American Society for Radiation Oncology (ASTRO) released a statement last week strongly opposing the extensive cuts to cancer research and Medicaid funding in the Fiscal Year 2018 budget released by the White House. The association said these substantial reductions in support for medical research and care would destabilize the progress toward finding cures and negatively impact cancer patients across the country.

Patients who were implanted with the BioZorb 3-D bioabsorbable marker during their lumpectomy could be treated with smaller radiation volumes than patients who did not receive the marker, according to new research. The findings were presented at the recent American Society of Breast Surgeons (ASBrS) annual meeting, April 26-30 in Las Vegas. The difference in volumes was statistically significant.